Rosen Law Firm Urges Outlook Therapeutics Investors To Act Before Deadline Following Alleged Securities Violations

Rosen Law Firm, a prominent global investor rights legal practice, has issued a call to action for investors who have acquired securities of Outlook Therapeutics, Inc. OTLK, urging them to seek legal counsel ahead of a crucial deadline. The company, specializing in the development and planned commercialization of monoclonal antibodies for ophthalmic conditions, is facing scrutiny regarding potential securities class action. This notice serves as a reminder to those who purchased company's shares within the timeframe of December 29, 2022, and August 29, 2023.

Lead Plaintiff Deadline Approaching

Investors are alerted to the impending lead plaintiff deadline on January 2, after which certain rights may expire. It's highly advised for shareholders who have sustained losses during the 'Class Period' to contact Rosen Law Firm to ensure their rights are protected and to potentially participate in any financial recovery resulting from the class action lawsuit.

About Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. is based in Cranbury, New Jersey, and is currently in the late stages of developing its cutting-edge biopharmaceutical products. The company's strategic focus on monoclonal antibodies in the ophthalmic sector positions it uniquely in the biotech arena. Their stock, OTLK, has been at the center of recent allegations that have prompted the call to action from Rosen Law Firm for investors.

Rosen, Law, Investors